#  Tiba in international academic collaboration to develop a multi-antigen SARS-CoV-2 vaccine platform  

 





September 01, 2020

 

 

 Working in collaboration with Tiba Biotech, a Boston-based venture founded in 2017, Rueping and his team are developing a heterologous prime/boost vaccination regimen using complimentary nanoparticle delivery technologies developed at KAUST and at MIT. Tiba’s fully synthetic mRNA vaccines target multiple coronavirus antigens, in addition to the spike protein. [See more ->](https://coronavirus.kaust.edu.sa/r3t/using-naturally-occurring-bacterial-gas-vesicles-to-develop-a-novel-vaccination-approach-to-the-sars-cov-2-virus/)



 

 

 



 

 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)